"Devyn brings a rare combination of scientific depth, operational leadership, and strategic perspective," said Nazli Azimi, Ph.D., Chief Executive Officer of Therna. "His experience across genetic ...
According to Morgan O’Gara of Blackrock Dental, dentists’ surgeries are no longer the austere, clinical spaces they used to be. “The traditional kind of ‘up the stairs, two surgery’ practices are gone ...
"Gene editing takes centre stage in FDA’s new rare disease approval pathway" was originally created and published by ...
Beam is advancing BEAM-304 using an approach in which multiple mutation-specific base editors are developed within a single clinical program.
New six-part webinar series on genetic causes of cerebral palsy launches Wednesday We are excited to partner with ...
Learn more about the cutting-edge technology that enables 3D printing inside living cells and what that means for the ...
The Food and Drug Administration aims to evaluate treatments for rare diseases based on plausible evidence that they would work — without requiring a clinical trial first.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results